IP Library Granted Patent US 9,359,410
Granted Patent B2
US 9,359,410 · App. 13/914,331 · Granted Jun 7, 2016

Virus like particle purification

Inventors: Thomas S. Vedvick (Bozeman, MT); Bryan Steadman (Bozeman, MT); Charles Richardson (Bozeman, MT); Thomas R. Foubert (Bozeman, MT); Charles R. Petrie (Bozeman, MT)
Assignee: TAKEDA VACCINES INC.
C07K14/005C07K1/18C12N7/00C12N2770/16023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,359,410
App. No.
13/914,331
Granted
Jun 7, 2016
Kind
B2
Abstract

Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.

Claims (13)

1. A method of purifying Calicivirus virus-like particles (VLPs) comprising contacting a solution containing said VLPs with at least one chromatographic material, wherein the at least one chromatographic material is an ion exchange chromatographic material, wherein the chromatographic materials used in the method do not comprise hydroxyapatite, and wherein the VLPs are purified to greater than about 70%.

2. The method of claim 1 , wherein the ion exchange chromatographic material is an anion exchange chromatographic material.

3. The method of claim 2 , wherein the anion exchange chromatographic material is a DEAE-Sepharose FF resin.

4. The method of claim 2 , wherein the method further comprises the use of a cation exchange chromatographic material.

5. The method of claim 1 , wherein the method further comprises the use of a hydrophobic interaction chromatographic material.

6. The method of claim 1 , wherein the method further comprises a precipitation step.

7. The method of claim 6 , wherein the precipitation step is a PEG precipitation step.

8. The method of claim 7 , wherein the PEG precipitation step is carried out prior to contacting the solution containing the VLPs with the ion exchange chromatographic material.

9. The method of claim 1 , wherein the VLPs are purified to greater than about 90%.

10. The method of claim 1 , wherein the method further comprises an ultrafiltration and/or diafiltration step.

11. The method of claim 1 , wherein the Calicivirus VLPs are Norovirus VLPs.

12. The method of claim 11 , wherein the Norovirus VLPs are Norovirus genogroup I or genogroup II VLPs.

13. The method of claim 12 , wherein the Norovirus genogroup I VLPs are Norovirus genotype I.1 VLPs.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2014
From: VEDVICK, THOMAS S; STEADMAN, BRYAN; RICHARDSON, CHARLES; FOUBERT, THOMAS R; PETRIE, CHARLES R
To: LIGOCYTE PHARMACEUTICALS INC
Reel/Frame 032329/0006 →
MERGER Recorded Feb 28, 2014
From: TAKEDA VACCINES (MONTANA) INC; INVIRAGEN INC
To: TAKEDA VACCINES INC.
Reel/Frame 032329/0076 →
CHANGE OF NAME Recorded Feb 28, 2014
From: LIGOCYTE PHARMACEUTICALS INC
To: TAKEDA VACCINES (MONTANA) INC
Reel/Frame 032376/0197 →
Continuity (3)
Continuation 12531248
Provisional Application 60906821 · Mar 14, 2007
Related Publication 20130344107A1 · Dec 26, 2013